The association of hepatic steatosis and fibrosis with heart failure and mortality

Table 5 Multivariable Cox regression analyses showing the association of advanced liver fibrosis (defined by BARD ≥ 2) with the risk of hospitalization for heart failure, all-cause mortality and cardiovascular mortality in patients with both NAFLD (defined by FLI ≥ 60) and previous heart failure

Advanced liver fibrosis	Model 1				Model 2			Model 3			Model 4
Advanced liver fibrosis	Events	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
hHF	213	1.456	1.027–2.065	0.035	1.162	0.811–1.665	0.413	1.127	0.786–1.616	0.517	1.089	0.758–1.565	0.644
All-cause mortality	169	1.994	1.267–3.138	0.003	1.615	1.017–2.566	0.042	1.656	1.038–2.639	0.034	1.597	1.001–2.548	0.049
CV mortality^a	33	5.525	1.051–29.053	0.044	5.476	1.031–29.088	0.046	5.787	1.097–30.538	0.039	5.454	1.047–28.400	0.044

CI confidence interval, CV mortality cardiovascular mortality, HR hazard ratio, hHF hospitalized heart failure
Model 1: crude
Model 2: age, sex and body weight
Model 3: model 2 + alcohol drinking, smoking, regular exercise, and income status
Model 4: model 3 + hypertension, dyslipidemia, and estimated glomerular filtration rate
^aDue to the small number of CV mortality events, Firth’s logistic regression was performed

ISSN: 1475-2840